Mutations in RNF43, which encodes the ubiquitin E3 ligase ring finger protein 43, were recently found in intraductal papillary mucinous neoplasms of the pancreas. We evaluated somatic mutations of RNF43 and the expression of ring finger protein 43 as well as their associations with the molecular and clinicopathological features in 176 surgically resected intraductal papillary mucinous neoplasms. Frozen tissues were available for 57 cases and were used for next-generation sequencing analysis of the entire coding exons of RNF43. Formalin-fixed and paraffinembedded tissues from all 176 cases were used for the immunohistochemical analysis of the expression of ring finger protein 43. Mutations detected with the next-generation sequencing analysis were validated by using Sanger sequencing. Statistical analysis was used to evaluate the associations between RNF43 aberrations and molecular and clinicopathological features including GNAS mutations, KRAS mutations, loss of SMA and MAD4 homologue expression, tumor protein 53 overexpression, tumor grade, histological type, mural nodule detection, macroscopic type, stage, recurrence, and survival. Somatic RNF43 mutations were found in 8 (14%) of the 57 examined cases, and included 5 frameshift mutations (p.F69fs, p.S264fs, p.L311fs, p.R363fs, and p.V490fs), 1 non-sense mutation (p.Q153X), and 2 missense mutations (p.I164N and p.P310A). The expression of ring finger protein 43 was downregulated in 52 (29.5%) of the 176 examined cases. RNF43 mutations were significantly associated with the downregulated expression of ring finger protein 43 (P ¼ 0.011), GNAS mutation (P ¼ 0.020), and mural nodule detection (P ¼ 0.038). The expression of ring finger protein 43 was not associated with any clinicopathological features except RNF43 mutation. These results indicate that RNF43 mutation might cause downregulation of the expression of ring finger protein 43 and play a crucial role and associate synergistically with GNAS mutation during development of intraductal papillary mucinous neoplasm of the pancreas.
Intraductal papillary mucinous neoplasm of the pancreas is a primarily non-invasive tumor characterized by a dilated, mucin-filled duct. 1 The dilated duct is lined with neoplastic epithelial cells exhibiting a papillary growth pattern with varying degrees of atypia and abundant mucin secretion; this appearance differs greatly from that of a conventional pancreatic cancer such as ductal adenocarcinoma that forms a highly invasive, firm mass. 2 However, intraductal papillary mucinous neoplasms often accompany or progress to ductal adenocarcinoma, resulting in a poor prognosis; therefore, intraductal papillary mucinous neoplasm is regarded as a precursor of ductal adenocarcinoma. 1 Currently, given the lack of appropriate biomarkers to monitor the disease phenotype, diagnosis and treatment of intraductal papillary mucinous neoplasms rely heavily on imaging studies in accordance with a guideline for the management of patients with these neoplasms, 3 thus indicating a pressing need to develop molecular markers on the basis of the molecular phenotypes. In 2011, it was discovered that intraductal papillary mucinous neoplasms often harbored mutations in GNAS and RNF43. [4] [5] [6] Most GNAS mutations found in intraductal papillary mucinous neoplasms are either R201H or R201C, which are known to induce gain of function of the encoded protein guanosine nucleotide-binding protein alpha. 7 In contrast, RNF43 mutations are mostly frameshift or nonsense mutations that are expected to induce a lossof-function of the encoded protein ring finger protein 43. 4, 5 Among pancreatic neoplasms, GNAS and RNF43 mutations are almost exclusively found in intraductal papillary mucinous neoplasms, and therefore such mutations are thought to play crucial roles in the characteristic phenotypes of intraductal papillary mucinous neoplasms. 4, 5 Ring finger protein 43 is a ubiquitin E3 ligase that targets the frizzled receptor via interactions with the R-spondin protein. 8 Ubiquitination of the frizzled receptor results in the blocking of signal transduction through the wingless-type MMTV integration site (Wnt) pathway; accordingly, loss of function of ring finger protein 43 leads to Wnt signaling activation and tumorigenesis in the colon. 8 RNF43 mutations have also been shown to confer Wnt dependency in pancreatic cancer cells. 9 However, the clinicopathological relevance of RNF43 mutations in intraductal papillary mucinous neoplasms remains unclear.
Herein, we evaluated RNF43 mutations and expression as well as the associations with the molecular and clinicopathological features of intraductal papillary mucinous neoplasms.
Materials and methods

Tissues
A total of 176 patients with intraductal papillary mucinous neoplasms who were surgically treated between 2001 and 2010 at the Tokyo Women's Medical University Hospital were evaluated. Formalin-fixed and paraffin-embedded tissues from the 176 patients were used for the immunohistochemical examination. Frozen tissues from 57 of the 176 patients were used for next-generation sequencing analysis. The clinicopathological features of the included cases are listed in Table 1 . This study was approved by the Ethics Committee of the Tokyo Women's Medical University.
Next-Generation Sequencing
Methanol-fixed and hematoxylin-stained frozen sections were prepared from frozen tissues. Tumor tissues were collected from each section by manual dissection under microscopic guidance. In noninvasive cases, a representative intraductal lesion in each case showing the highest grade of atypia was Sanger Sequencing DNA samples obtained from frozen tissues or formalin-fixed and paraffin-embedded tissues were used in a Sanger sequencing analysis to validate the RNF43 mutation statuses and detect GNAS and KRAS mutations as described previously. 4 The primers used to validate the RNF43 mutation statuses are listed in Table 2 . The primers used to detect GNAS and KRAS mutations were described previously. 4 
Immunohistochemical Analysis
Indirect streptavidin-biotin immunohistochemical staining of paraffin-embedded tissues was performed by using a rabbit polyclonal anti-ring finger protein 43 antibody (Atlas Antibodies, Stockholm, Sweden) and a Histofine SAB-PO kit (Nichirei Bioscience Inc., Tokyo, Japan) according to the manufacturers' instructions. To evaluate the staining specificity, a negative control staining condition (no primary antibody) was performed. The immunohistochemical results were evaluated as either reduced or retained expression by comparing the staining intensity of each sample with that of an islet of Langerhans in the same section because the islet of Langerhans showed consistent staining that was easy to identify and evaluate compared with normal ducts that were often devastated by obstructive pancreatitis cause by the neoplasm. The staining was evaluated blindly from sequencing results at lesions with the highest grade of atypia or invasive area in each case. SMA and MAD4 homolog (SMAD4) and tumor protein 53 (TP53) expression were examined by using a mouse monoclonal anti-SMAD4 antibody (B-8; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and a mouse monoclonal anti-p53 antibody (DO-7; Dako, Glostrup, Denmark) as described previously. 10 
Statistics
The statistical analysis incorporated the chi-squared test for comparisons between the molecular and clinicopathological data, and Kaplan-Meier analysis with the log-rank test for survival analyses. Analyses were performed using the PASW Statistics software package (version 18.0; SPSS Inc., Chicago, IL, USA). P-values of o0.05 were considered as statistically significant.
Results
We performed sequencing analyses of all coding exons of RNF43 in the 57 patients for whom frozen tissues were available; the analysis was conducted via semiconductor sequencing in 56 samples and via massively parallel sequencing as a whole exome analysis in 1 sample. We obtained the sequence data at an average read depth of 2664 with semiconductor sequencing. The called variations were validated by using tumor DNA, and the somatic state was examined via Sanger sequencing analysis of normal DNA. The massively parallel sequencing data obtained from the single case had been reported previously. 4 As a result, we found that 8 (14%) of the 57 intraductal papillary mucinous neoplasms harbored somatic RNF43 mutations, including 5 frameshift mutations, 1 non-sense mutation, and 2 missense mutations ( Figure 1 ; Table 3 ). Of these mutations, 3 of the 5 frameshift mutations, specifically p.F69fs, p.S264fs, and p.L311fs, as well as the non-sense mutation p.Q153X occurred upstream of (Figure 1 ). SIFT (http://sift.jcvi.org/) 12 and PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/ index.shtml), 13 the online programs used to predict the functional significance of the missense mutations, predicted that both these missense mutations would have damaging effects.
Next, we investigated the expression of ring finger protein 43 in 176 formalin-fixed and paraffinembedded tissues of intraductal papillary mucinous neoplasms via immunohistochemical analysis. Because intraductal papillary mucinous neoplasm is intrinsically a heterogeneous lesion, some cases showed heterogeneity of staining, so that we evaluated the staining at areas showing the highest grade of atypia or invasive area with comparison with staining of islet cells. As a result, the expression of ring finger protein 43 was reduced in 52 (29.5%) of the 176 examined tissues relative to the normal islet cells (Figure 2 ). This reduced expression was significantly associated with the presence of somatic mutations in all but two cases, specifically the case with the p.R363fs frameshift mutation and the case with the p.P310A missense mutation (P ¼ 0.011).
We evaluated the association between RNF43 mutations or the expression of ring finger protein 43 and the molecular and clinicopathological features, including GNAS mutations, KRAS mutations, SMAD4 downregulation, TP53 overexpression, tumor grade, histological type, mural nodule detection, macroscopic type, stage, recurrence, and survival. We found that RNF43 mutation was significantly associated with GNAS mutations (P ¼ 0.020) and mural nodule detection (P ¼ 0.038; Table 4 ). RNF43 expression was not associated with any of the features (Table 4) .
Discussion
In this study, we found that 8 (14%) of the 57 intraductal papillary mucinous neoplasms harbored somatic RNF43 mutations. Among these mutations, 3 of 5 frameshift mutations and 1 non-sense mutation were expected to yield truncated proteins lacking the protease-associated domain and/or the ring finger domain, whereas 2 missense mutations affected conserved residues in the protease-associated domain or the ring finger domain and would likely result in the functional abrogation of ring finger protein 43. The remaining two frameshift mutations would yield truncated ring finger protein 43 immediately downstream of the ring finger The RNF43 mutations were associated with GNAS mutations and mural nodule detection. GNAS mutations have been found in 40-60% of intraductal papillary mucinous neoplasms, and are known to be exclusive to these tumors among the various pancreatic neoplasms. [4] [5] [6] Komatsu et al 16 reported that GNAS mutations induced the upregulation of cyclic adenosine monophosphate and overexpression of mucin protein genes in some pancreatic duct-lineage cells; therefore, GNAS mutation appears to play a key role in the secretion of abundant mucin, the most prominent characteristic phenotype of intraductal papillary mucinous neoplasms. Interestingly, the same authors also demonstrated that the exogenous expression of mutated GNAS did not confer a proliferative advantage on pancreatic cancer cells. 16 These results regarding the association between RNF43 and GNAS mutations might indicate that the loss-of-function of ring finger protein 43 would confer an advantage with respect to proliferation and/or maintenance upon pancreatic ductal cells with GNAS mutations in intraductal papillary mucinous neoplasms. Amato et al 15 also indicated that RNF43 mutation was associated with GNAS mutation. The mural nodule indicates the protuberance of a neoplasm into the pancreatic ductal lumen; this is considered to indicate a high-grade lesion. 3 The association between the mural nodule and RNF43 mutation suggests that ring finger protein 43 might confer proliferative advantages that lead to protruding neoplasms. However, no associations were identified between RNF43 mutation and various clinicopathological features including the histological type, tumor grade, stage, and prognosis, possibly indicating that RNF43 mutation is an early developmental event with no significant impact on the progression of the histological type, dysplastic grade, or tumor stage of intraductal papillary mucinous neoplasms.
We found that 52 (29.5%) of the 176 intraductal papillary mucinous neoplasms exhibited reduced expression of ring finger protein 43. To the best of our knowledge, this is the first report to reveal aberrant expression of ring finger protein 43 in intraductal papillary mucinous neoplasms. The reduced expression of ring finger protein 43 was associated with RNF43 mutation, which indicates that RNF43 mutation may lead to reduced expression of ring finger protein 43. Indeed, most RNF43 mutations are truncating mutations and as a result, protein expression will likely be reduced. However, because the reduced expression of ring finger protein 43 was observed more frequently than were mutations, epigenetic alterations might be responsible for this reduced expression in addition to somatic mutations, a possibility that will be addressed in a future study. The reduced protein expression was not associated with any clinicopathological features, indicating that the aberrant expression of ring finger protein 43 might play a role in the development but not in the progression of intraductal papillary mucinous neoplasms.
In conclusion, the results of this study indicate that RNF43 mutation might cause reduced expression of ring finger protein 43 and play a crucial role and associate synergistically with GNAS mutation in development of intraductal papillary mucinous neoplasms of the pancreas.
